Long‐Term Oncologic Outcomes of Neoadjuvant Tumor‐Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial
Biochemical recurrence (BCR) following radical prostatectomy (RP) occurs in 20%–40% of patients with localized prostate cancer. Neoadjuvant PROSTVAC has been shown to enhance T‐cell infiltration into the tumor immune microenvironment, but whether these immunologic changes translate into improved long‐term oncologic out...